Maternal inflammation as indicated by the presence in maternal blood of early gestational C-reactive protein, an established inflammatory biomarker, appears to be associated with greater risk for schizophrenia in offspring, according to researchers at Columbia University.
The Columbia researchers with colleagues in Finland conducted an analysis of data from the Finnish Prenatal Study of Schizophrenia, a large, national birth cohort with an extensive bio-bank. They tested for the presence of C-reactive protein in the maternal blood of 777 offspring with schizophrenia and compared the findings with those from 777 control subjects. Maternal C-reactive protein levels were assessed from archived maternal serum specimens.
They found that increasing maternal C-reactive protein levels were significantly associated with development of schizophrenia in offspring and remained significant after adjusting for potential confounders such as parental history of psychiatric disorders, twin/singleton birth, location of birth, and maternal socioeconomic status. For every 1 mg/L increase in maternal C-reactive protein, the risk of schizophrenia increased by 28%.
This is the first time that this association has been demonstrated, indicating that an infection or increased inflammation during pregnancy could increase the risk of schizophrenia in the offspring. Inflammation has been shown to alter brain development in previous studies, and schizophrenia is a neurodevelopmental disorder. Thus, this study provides an important link between inflammation and schizophrenia and may help the medical community to better understand the biological mechanisms that lead to this disorder. To the extent that the increased inflammation is due to infection, this work may suggest that approaches aimed at preventing infection may have the potential to reduce risk of schizophrenia. There are many other known causes of inflammation, including tissue injury and autoimmune disease, although the researchers did not examine these specific conditions in this study.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.